Previous 10 | Next 10 |
Cancer patients who receive an antibiotic within one month of receiving a checkpoint inhibitor achieve a median survival of just two months. Those who don't take an antibiotic and receive the same treatment achieve a median survival of 26 months, fully 1,200% longer. The significant gap is thoug...
SOUTH SAN FRANCISCO, Calif., Aug. 09, 2019 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced a grant of induc...
Dr. McHutchison is a world-renowned hepatologist, gastroenterologist, and anti-viral drug developer He led the research and development of five marketed therapies for chronic hepatitis B and chronic hepatitis C Succeeds Derek Small, Co-Founder of Assembly Biosciences, who will cont...
Assembly Biosciences (NASDAQ: ASMB ): Q2 GAAP EPS of -$0.72 beats by $0.43 . More news on: Assembly Biosciences, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
SOUTH SAN FRANCISCO, Calif., Aug. 05, 2019 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today reported financial results...
The first patient has been dosed in a Phase 1b clinical trial evaluating Assembly Biosciences' ( ASMB +3.4% ) ABI-M201 in patients with mildly to moderately active ulcerative colitis (UC). More news on: Assembly Biosciences, Inc., Healthcare stocks news, Stocks on the move, Read ...
First oral microbiome biologic drug candidate from Assembly’s novel microbiome platform to enter clinical trials in patients ABI-M201 utilizes Assembly’s proprietary and patented Gemicel ® capsule-in-capsule delivery system for targeted delivery into the GI tract ...
SAN FRANCISCO, June 25, 2019 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced participation in the Microbiom...
SAN FRANCISCO, June 21, 2019 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced that Richard Colonno, PhD, Exe...
The following slide deck was published by Assembly Biosciences, Inc. in conjunction with this Read more ...
News, Short Squeeze, Breakout and More Instantly...
Assembly Biosciences Inc. Company Name:
ASMB Stock Symbol:
NASDAQ Market:
Assembly Biosciences Inc. Website:
2024-07-16 14:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
– Data from both ABI-5366 and ABI-1179, novel long-acting helicase-primase inhibitor candidates for recurrent genital herpes, to be presented – – Poster presentation highlights key preclinical data from ABI-5366 supporting its entry into ongoing Phase 1a/b clinical ...
SOUTH SAN FRANCISCO, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced that the first participant has been dosed in the Phase 1b trial of ABI-4334, a nex...